The MS Wire

News, info and tips for living with multiple sclerosis

Tag: tolebrutinib

Renewed Hope for BTK Inhibitor MS treatments

Researcher working in laboratory

Earlier this year, I wondered whether it was time to give up my hope that researchers were close to developing a Bruton tyrosine kinase (BTK) inhibitor – a treatment that could pump the brakes on multiple sclerosis (MS) progression, particularly in primary progressive MS (PPMS). The US Food and Drug Administration (FDA) had just decided not to approve the experimental BTK inhibitor tolebrutinib in its current form. But the findings…Continue Reading

Tolebrutinib nears the MS approval finish line

Woman runs toward finish line, like tolebrutinib is

After some stumbles out of the starting gate, an experimental treatment that’s in a group hoping to be the next big thing for people with multiple sclerosis (MS) is a step closer to U.S. Food and Drug Administration (FDA) approval. Tolebrutinib, developed by Sanofi, has been designated as a Breakthrough Therapy for the treatment of adults with non-relapsing secondary progressive MS (nrSPMS). The designation is intended to speed the development…Continue Reading

A Little Stumble for BTKi’s

BTK's are molecules

A little over a year ago, I wrote about whether Bruton’s tyrosine kinase inhibitors (BTKi’s) might be the next big thing in multiple sclerosis (MS) treatments. BTKi’s are small molecules that selectively block an enzyme that’s important for the activation of B-cells in the immune system and microglia, cells whose job is to protect neurons. Some of both types of cells are thought to be responsible for the abnormal immune…Continue Reading